Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information

Matti Aapro¹ · Mark Clemons² · Lee Schwartzberg³ · David Warr⁴

Received: 31 January 2018 / Accepted: 20 February 2018 / Published online: 19 March 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Release Date: March 15, 2018

Expiration Date: March 15, 2019

Target audience

This educational activity is specifically designed to meet the needs of oncologists, registered nurses, and other healthcare professionals involved in the treatment of patients with chemotherapy-induced nausea and vomiting (CINV).

Learning objectives

Upon successful completion of this educational activity, participants should be able to:

- Identify the treatment and patient risk factors for CINV
- Incorporate recent changes to the clinical guidelines for CINV management into routine practice
- Describe recent clinical trial data evaluating neurokinin-1 (NK-1) receptor antagonists
- Determine the role of a CINV risk factor toolkit to optimize individual patient management

✉ Matti Aapro
maapro@genolier.net

¹ Cancer Centre, Clinique de Genolier, Case Postale (PO Box) 100, Route du Muils 3, 1272 Genolier, Switzerland

² The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada

³ The West Clinic, Memphis, TN, USA

⁴ Princess Margaret Cancer Center, Toronto, Ontario, Canada

Provider

This activity is provided by prIME Oncology.

Continuing education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this journal-based CME activity for a maximum of *1 AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center's COA.

A maximum of 1 contact hour may be earned for successful completion of this program. Successful completion includes reviewing the journal supplement and completing the evaluation.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation's Independent Learning Needs Assessment (ILNA) renewal method. Visit www.oncc.org for complete details on oncology nursing certification.

Method of participation and request for credit

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.

Please visit <https://goo.gl/mszn1P> to take the posttest.

In order to claim credit for this activity, a score of 75% or higher is required.

Disclosure of relevant financial relationships

prIME Oncology assesses relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

The employees of prIME Oncology have disclosed:

- Robert Coleman, MD, FRCP (medical director content reviewer/planner), discloses that he has done contracted research for or received research support from Amgen and Bayer.
- Ronald Viggiani, MD (medical director content reviewer/planner)—no relevant financial relationships
- Zachary Hartman, PhD (scientific content reviewer/planner), discloses that he is a stockholder of Advaxis, Inc. and Ariad Pharmaceuticals.
- Tristin Abair, PhD (medical writer content reviewer/planner)—no relevant financial relationships
- Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner)—no relevant financial relationships

- Trudy Grenon Stoddert, ELS (editorial content reviewer)—no relevant financial relationships

Disclosure of unlabeled use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Acknowledgements The author would like to thank Tristin Abair, PhD, for her assistance in drafting the manuscript and Trudy Grenon Stoddert, ELS, for her editorial assistance and assistance with preparing the manuscript for submission.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Financial Support This educational activity is supported by grants from Merck and Co, Inc. and TESARO, Inc.

Compliance with ethical standards

Conflict of interest Dr Aapro has disclosed that he has received consulting fees or honoraria from Amgen. He has also received payment for lectures and/or support for travel from Amgen, Helsinn, Hospira, Johnson and Johnson, Novartis, Pierre Fabre Medicament, Roche, Sandoz, TESARO, Teva, and Vifor Pharma. Dr Aapro has received research funding from Helsinn, Hospira, Novartis, Pierre Fabre Medicament, and Sandoz. He has also disclosed receiving fees for participation in advisory or review activities from Helsinn Healthcare, Hospira, Merck, Merck KGaA, Pierre Fabre Medicament, Sandoz, TESARO, Teva, and Vifor Pharma. Dr Clemons has no relevant financial relationships to disclose. Dr Schwartzberg has disclosed that he has received consulting fees or honoraria from Eisai, Helsinn, Heron, and TESARO. He also discloses that he has received research funding from TESARO, and fees for participation in advisory or review activities from Helsinn and Heron. Dr Warr has disclosed that he has received consulting fees or honoraria from Helsinn and Merck. He also discloses that he has received payment for lectures and participation in advisory or review activities from Merck.